Your browser doesn't support javascript.
COVID-19-related encephalopathy presenting with aphasia resolving following tocilizumab treatment.
Muccioli, Lorenzo; Pensato, Umberto; Cani, Ilaria; Guerra, Luca; Provini, Federica; Bordin, Giorgio; Riccioli, Luca Albini; Lodi, Raffaele; Tinuper, Paolo; Bisulli, Francesca.
  • Muccioli L; Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.
  • Pensato U; Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.
  • Cani I; Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy.
  • Guerra L; Infectious Diseases Unit, AOSP and AUSL Bologna, Bologna, Italy.
  • Provini F; Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the ERN EpiCARE, Bologna, Italy.
  • Bordin G; Piccole Figlie Hospital, Parma, Italy.
  • Riccioli LA; IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the ERN EpiCARE, Bologna, Italy.
  • Lodi R; Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the ERN EpiCARE, Bologna, Italy.
  • Tinuper P; Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the ERN EpiCARE, Bologna, Italy.
  • Bisulli F; Department of Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the ERN EpiCARE, Bologna, Italy. Electronic address: francesca.bisulli@unibo.it.
J Neuroimmunol ; 349: 577400, 2020 12 15.
Article in English | MEDLINE | ID: covidwho-792960
ABSTRACT
Encephalopathy is emerging as a recurrent complication of COVID-19 yet remains poorly characterized. We report the case of a middle-aged woman with COVID-19-related encephalopathy presenting as expressive aphasia and inattentiveness, subsequently progressing to agitation and marked confusion. Brain MRI and CSF analysis were unremarkable, while EEG showed slowing with frontal sharp waves. Neuropsychiatric symptoms resolved following treatment with tocilizumab. CNS involvement in COVID-19 may present as a subacute encephalopathy characterized by prominent frontal lobe dysfunction, with language disturbances as first neurological manifestation. Future studies should further investigate the role of tocilizumab in treating COVID-19-related encephalopathy.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Aphasia / Brain Diseases / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / COVID-19 Type of study: Case report Topics: Long Covid Limits: Female / Humans / Middle aged Language: English Journal: J Neuroimmunol Year: 2020 Document Type: Article Affiliation country: J.jneuroim.2020.577400

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Aphasia / Brain Diseases / Antibodies, Monoclonal, Humanized / Cytokine Release Syndrome / COVID-19 Type of study: Case report Topics: Long Covid Limits: Female / Humans / Middle aged Language: English Journal: J Neuroimmunol Year: 2020 Document Type: Article Affiliation country: J.jneuroim.2020.577400